Sabby Management’s AVEO Pharmaceuticals, Inc. AVEO Stock Holding History

Sabby Management’s Portfolio AVEO Stock Details AVEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-620	Closed	-$454K	–	204
2021 Q1	$454K	Sell	620 -6,851	-92%	-$59.1K	0.09%	115
2020 Q4	$4.31M	Buy	7,471 +670	+10%	+$3.84K	0.83%	23
2020 Q3	$4.04M	Sell	6,801 -506	-7%	-$2.5K	0.6%	30
2020 Q2	$3.76M	Sell	7,307 -2,941	-29%	-$18.6K	0.76%	22
2020 Q1	$2.41M	Buy	10,248 +9,163	+845%	+$45.5K	1%	14
2019 Q4	$673K	Buy	1,085 +495	+84%	+$3.64K	0.19%	27
2019 Q3	$498K	Buy	590 +69	+13%	+$513	0.27%	37
2019 Q2	$744K	Buy	+521	New	+$4.46K	0.94%	22

Other funds holding AVEO

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

JGC

J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Sabby Management's AVEO Position: Q2 2021 in Review

Sabby Management sold out of AVEO Pharmaceuticals, Inc. (AVEO) in Q2 2021, closing a stake of 10,815 shares — an estimated $79K sold.

Sabby Management first reported a position in AVEO in Q4 2013 and held it in 9 quarters. The position peaked at $2.74M in Q4 2013. 63 funds tracked by Wall St. Rank hold AVEO as of Q2 2021.

Sabby Management reported no remaining AVEO Pharmaceuticals, Inc. position as of Q2 2021 after selling out during the quarter.
Sabby Management sold 10,815 AVEO Pharmaceuticals, Inc. shares in Q2 2021, an estimated $79K.
Sabby Management first reported a position in AVEO Pharmaceuticals, Inc. in Q4 2013 and held it in 9 quarters.
Sabby Management's AVEO Pharmaceuticals, Inc. position peaked at $2.74M in Q4 2013.
63 funds tracked by Wall St. Rank held AVEO Pharmaceuticals, Inc. as of Q2 2021.

Based on Sabby Management's 13F filing for Q2 2021, filed 16 Aug 2021.